FIGURE

Fig. 2

ID
ZDB-FIG-221119-21
Publication
Wei et al., 2022 - Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP
Other Figures
All Figure Page
Back to All Figure Page
Fig. 2

a Structural superimposition of ZG180/SaClpP and ZG180/HsClpP complexes to reveal the strategy for designing selective activators for SaClpP over HsClpP. SaClpP and HsClpP are shown in gray and wheat cartoon tubes, respectively. ZG180 is colored in cyan in the ZG180/SaClpP structure, while it is colored in yellow in the ZG180/HsClpP structure. I91 in SaClpP and W146 in HsClpP are shown as a stick. b Structures of SaClpP activators (R)- and (S)-ZG197 developed by the structure-based design outlined in (a). The chiral methyl group is indicated in red. c Quantitation of α-casein hydrolysis by SaClpP and HsClpP in the presence of (R)- and (S)-ZG197, respectively (n = 3 biologically independent experiments). Data are presented as mean ± SD (error bars). d Effect of activators on degradation of the cellular SaFtsZ protein with the supplement of bovine serum albumin (BSA), the recombinant SaClpP, and HsClpP, respectively, in cell lysates of the clpP deletion (ΔclpP) mutant. The abundance of cellular SaFtsZ is quantitated with a Western blot assay. Quantitation on the band intensity of SaFtsZ is normalized against the loading control of SaGAPDH, and the ratio in the DMSO group is considered as 1.0. Source data are provided as a Source Data file.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Nat. Commun.